REPLIGEN CORP (RGEN) is drawing unusual attention today. Our newswire has captured 3 stories on RGEN across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 62/100).
Repligen Corporation (RGEN) shares surged 10.90% to $145.34 in Monday trading, driven by a strong earnings report and raised full-year guidance. The biotechnology firm reported better-than-expected second-quarter results, including a 12% year-over-year revenue increase and an upward revision to its 2026 financial outlook. The stock's rally reflects investor optimism over the company's performance and strategic initiatives.
Repligen reported second-quarter revenue of $204.1 million, a year-over-year increase of 12%. Non-GAAP earnings per share were $0.54, beating estimates by $0.09. The company also raised its full-year 2026 guidance, projecting adjusted EPS of $2.03 to $2.09, up from the previous range of $1.97 to $2.05. Revenue guidance was lifted to $813 million to $834 million for 2026. These results were highlighted in a July 28, 2026 earnings call and disclosed in a Form 8-K filed with the SEC. The company attributed the strong performance to 13% organic growth and the planned acquisition of BioLife Solutions, which is expected to expand its cell therapy business.
Repligen's stock closed at $145.34, a 10.90% increase from the prior session. The stock is currently trading within its 52-week range of $100.99 to $175.77. The company has a market capitalization of $7.4 billion and a P/E ratio of 144.0. Trailing twelve-month revenue grew 17.4%, and the firm maintains a net margin of 6.7%. Recent insider transactions include two sales by the CFO totaling $186,000. No unusual options activity or social media chatter was reported in the last 24 hours.
Repligen has not scheduled an upcoming earnings date. Investors should monitor the breadth of analyst coverage and any further developments regarding the BioLife Solutions acquisition.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Shares in Biopharma manufacturing company Repligen Corporation ($RGEN) raced 3% higher in early trading today after blockbuster results and a top analyst declaring ...
Canaccord reiterates Hold on Repligen stock, keeps $145 target
Repligen (NASDAQ:RGEN) reported second-quarter 2026 revenue of $204 million, up 12% year over year on a reported basis and 13% organically, as demand for proteins, analytics products and recurring consumables supported growth. The company also raised its full-year organic revenue growth and adjusted
REPLIGEN CORP (RGEN) is drawing unusual attention today. Our newswire has captured 3 stories on RGEN across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 62/100). The most recent driver: "Repligen Stock (RGEN) Rises After Investors Wowed By ‘Market Leading’ Q2 Figures" (TipRanks).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of RGEN coverage reads 62/100 over 3 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on RGEN: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier RGEN move explainers: 2026-07-29 · 2026-07-28 · 2026-07-22